Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity

Expert Opinion on Emerging Drugs

Volumn 13, Issue 2, 2008, Pages 383-392

  Supuran, Claudiu T ^a,b   Di Fiore, Anna ^a   De Simone, Giuseppina ^a  

^a CNR   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antiobesity drugs; Carbonic anhydrase; Lipogenesis; Topiramate; Zonisamide

Indexed keywords

ACETAZOLAMIDE; ADIPONECTIN; AGOUTI RELATED PROTEIN; ALPHA INTERMEDIN; AMPHETAMINE; ANTIOBESITY AGENT; BROMOCRIPTINE; CARBONATE DEHYDRATASE INHIBITOR; COCAINE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ETHOXZOLAMIDE; FENFLURAMINE; GHRELIN; INSULIN; LEPTIN; LIRAGLUTIDE; MELANOCORTIN 4 RECEPTOR; METHAZOLAMIDE; MULTIVITAMIN; NEUROPEPTIDE Y; OCTREOTIDE; PHENTERMINE; PHENTERMINE RESIN; PROOPIOMELANOCORTIN; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNINDEXED DRUG; ZONISAMIDE;

ABDOMINAL CRAMP; BLOOD PRESSURE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; ENZYME INHIBITION; FATIGUE; FECES INCONTINENCE; FLATULENCE; GASTROINTESTINAL IRRITATION; HUMAN; INCREASED APPETITE; LIBIDO DISORDER; MALAISE; METABOLIC ACIDOSIS; MYOPIA; NAUSEA; NEPHROLITHIASIS; NONHUMAN; OBESITY; PARESTHESIA; PROPHYLAXIS; PULSE RATE; REVIEW; SIDE EFFECT; SKIN TINGLING; SLEEP DISORDER; STEATORRHEA; TASTE DISORDER; VALVULAR HEART DISEASE; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; CARBONIC ANHYDRASE INHIBITORS; CYTOSOL; FRUCTOSE; HUMANS; ISOXAZOLES; MITOCHONDRIA; OBESITY;

EID: 46849121802     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.13.2.383     Document Type: Review

References (75)

1. Friedman JM. A war on obesity, not the obese. Science 2003;299:856-9
2. Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science 2003;299:853-5
3. Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 2006;29:277-302
4. Campfield LA, Smith FJ, Burn P. Strategies and potential molecular targets for obesity treatment. Science 1998;280:1383-7
5. International Obesity Task Force. Available from: http://www.iotf.org [Last accessed 3 March 2008]
6. Ethan M, Berke MD, Nancy E, Morden MD. Medical management of obesity. Am Fam Physician 2000;62:419-26
7. Lyznicki JM, Young DC, Riggs JA, Davis RM. Obesity: assessment and management in primary care. Am Fam Physician 2001;63:2185-96
8. Despres JP, Lemieux S, Lamarche B, et al. The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Int J Obes Relat Metab Disord 1995;19(Suppl l):S76-86
9. Van Gaal L, Mertens I. Effects of obesity on cardiovascular systems and blood pressure control, digestive disease and cancer. In: Kopelman P, editor. Clinical obesity. Oxford: Blackwell; 1998. p. 205-25
10. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004;8:1-182
11. Chaput JP, Tremblay A. Current and novel approaches to the drug therapy of obesity. Eur J Clin Pharmacol 2006;62:793-803
12. Cheetham SC, Jackson HC, Vickers SP, et al. Novel targets for the treatment of obesity: a review of progress. Drug Discov Today Ther Strateg 2004; 1:227-35
13. Bays H, Dujovne C. Pharmacotherapy of obesity: currently marketed and upcoming agents. Am J Cardiovasc Drugs 2002;2:245-53
14. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther 1992;51:642-6
15. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluraminephentermine. N Engl J Med 1997;337:581-8
16. McNelly W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998;56:1093-124
17. Uscombe GP, Hopcroft RH, Thomas PC, Buckett WR. The contribution of metabolites to the rapid and potent down regulation of rat cortical beta adrenoreceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 1989;28:129-34
18. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7:189-98
19. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-25
20. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-7
21. Sidhaye A, Cheskin LJ. Pharmacologic treatment of obesity. Adv Psychosom Med 2006;27:42-52
22. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999;281:235-42
23. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998;21:1288-94
24. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-72
25. Mittendorfer B, Ostlund RE Jr, Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001;9:599-604
26. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000;160:1321-6
27. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1 year randomized controlled trial. Diabetes Care 2002;25:1033-41
28. Lindgärde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000;248:245-54
29. Rössner S, Sjöström L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000;8:49-61
30. Gadde KM. Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:549-56
31. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.; for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75
32. Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroeneterology 2007;132:2239-52
33. Rucker D, Padwall R, LI SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194-9
34. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004;12:1197-211
35. Obici S, Feng Z, Arduini A, et al. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat Med 2003;9:756-61
36. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-89
37. Supuran CT. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin Ther Patents 2003;13:1545-50
38. Tripp BC, Smith K, Ferry JG. Carbonic anhydrase: new insights for an ancient enzyme. J Biol Chem 2001;276:48615-8
39. Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Patents 2000;10:575-600
40. Supuran CT, Scozzafava A. Applications of carbonic anhydrase inhibitors and activators in therapy. Expert Opin Ther Patents 2002;12:217-42
41. Supuran CT, Scozzafava A, Conway J, editors. Carbonic anhydrase: its inhibitors and activators. Boca Raton, FL: CRC Press; 2004
42. Dodgson SJ. Inhibition of mitochondrial carbonic anhydrase: a discrepancy examined. J Appl Physiol 1987;63:2134-41
43. Dodgson SJ, Cherian K. Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis. Am J Physiol 1989;257:E791-6
44. Spencer IM, Hargreaves I, Chegwidden WR. Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust. Biochem Soc Trans 1988;16:973-4
45. Chegwidden WR, Spencer IM. Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus. Comp Biochem Physiol 1996;115B:247-54
46. Chegwidden WR, Dodgson SJ, Spencer IM. The roles of carbonic anhydrase in metabolism, cell growth and cancer in animals. In: Chegwidden WR, Edwards Y, Carter N, editors. The carbonic anhydrases: new horizons. Birkhäuser, Basel; 2000. p. 343-63
47. Lynch CJ, Fox H, Hazen SA, et al. Role of hepatic carbonic anhydrase in de novo lipogenesis. Biochem J 1995;310:197-202
48. Hazen SA,Waheed A,Sly WS,et al. Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes. FASEB J 1996;10:481-90
49. Atwood PV. The structure and mechanism of action of pyruvate carboxylase. Int J Biochem Cell Biol 1995;27:231-49
50. Alldred JB, Reilly KE. Short-term regulation of acetyl CoA carboxylase in tissues of higher animals. Prog Lipid Res 1997;35:371-85
51. Forster RE, Dodgson SJ. Membrane transport and provision of substrates for carbonic anhydrase in vertebrates. In: Chegwidden WR, Edwards Y, Carter N, editors. The carbonic anhydrases: new horizons. Birkhäuser Verlag, Basel; 2000. p. 263-80
52. Parkkila S. An overview of the distribution and function of carbonic anhydrase isozymes in mammals. In: Chegwidden WR, Edwards Y, Carter N, editors. The carbonic anhydrases: new horizons, Birkhäuser Verlag, Basel; 2000. p. 79-94
53. Parkkila S, Parkkila AK, Kivelä J. Role of carbonic anhydrase and its inhibitors in biological science related to gastroenterology, neurology and nephrology. In: Chegwidden WR, Edwards Y, Carter N, editors. The carbonic anhydrases: new horizons. Birkhäuser, Basel; 2000. p. 283-301
54. Bartlett JD, Jaanus SD. Clinical ocular pharmacology. Boston, MA: Butterworth; 1989
55. Maren, TH. Role of carbonic anhydrase in aqueous humor and cerebrospinal fluid formation. In: Segal MB, editor. Barriers and fluids of the eye and brain. London: MacMillan Press; 1992. p. 37-48
56. Maren TH. The development of topical carbonic anhydrase inhibitors. J Glaucoma 1995;4:49-62
57. Maren TH. Carbonic anhydrase: chemistry, physiology and inhibition. Physiol Rev 1967;47:595-781
58. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia 1994;35:450-60
59. Edmonds HL, Jiang YD, Zhang PY, Shank RP Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy. Life Sci 1996;59:PL127-31
60. Stringer JL. A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat. Epilepsy Res 2000;40:147-53
61. Sabers A, Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 2000;60:23-33
62. Bourgeois BFD. Pharmacokinetics and pharmacodynamics of topiramate. J Child Neurol 2000; 15:S27-30
63. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: summary of the Fifth Eilat Conference. Epilepsy Res 2001;43:11-58
64. Gordon A, Price LH. Mood stabilization and weight loss with topiramate. Am J Psychiatry 1999;156:968-9
65. Picard F, Deshaies Y, Lalonde J, et al. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res 2000;8:656-63
66. Mancini MC, Halpern A. Investigational therapies in the treatment of obesity. Expert Opin Investig Drugs 2006;15:897-915
67. Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett 2003;13:841-5
68. Chen RF, Kernohan JC. Combination of bovine carbonic anhydrase with a fluorescent sulfonamide. J Biol Chem 1967;242:5813-23
69. Vitale RM, Pedone C, Amodeo P, et al. Carbonic anhydrase inhibitors: molecular modeling study for the interaction of zonisamide and topiramate with isozyme va. Bioorg Med Chem 2007;15:4152-8
70. Zareba G. Zonisamide: review of its use in epilepsy therapy. Drug Today (Barc) 2005;41:589-97
71. Canitano R. Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev 2005;27:228-32
72. Kim CS. Zonisamide effective for weight loss in women. J Fam Pract 2003;52:600-1
73. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289:1820-5
74. De Simone G, Di Fiore A, Menchise V, et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett 2005;15:2315-20
75. Masuda Y, Karasawa T. Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneimittelforschung 1993;43:416-8